Samsung Epis Holdings Q1 2026: Profit Intact, Cash Bleeds ₩315.6B
A biosimilar holdco's debut full quarter: a 20% operating margin obscures a ₩315.6 billion operating cash deficit funded entirely by new short-term bank debt.
Source: Q1 2026 Quarterly Report (Period 2, Q1) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Samsung Epis Holdings Q1 2026: Profit Intact, Cash Bleeds ₩315.6B”
This article became available on June 7, 2026. Subscribe to read in full, or wait until September 5, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.
You just read what happened. Here's how to read what it means.
LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.
We read this company's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the full reportReading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.
